---
title: An FDA-Cleared Trial Will Test Engineered Immune Cells Against Advanced Colorectal Cancer
description: An early trial at CU Anschutz will test engineered immune cells against advanced colorectal cancer, a solid tumor where CAR-T has mostly failed.
author: Darie Nani (Editor-in-Chief)
updated: 2026-09-10T23:29:49.912Z
canonical: https://richhealthmagazine.com/article/car-t-colorectal-cancer-fda-trial-cu-anschutz
image: https://cdn.nanimediahouse.com/pexels-two-scientists-working-in-a-well-equipped-laboratory-with-mi-4031417.jpg
categories: Longevity & Science
content_type: News
region: United States
publication: Rich Health Magazine
schema_type: Article
---

The Food and Drug Administration has cleared investigators at the [University of Colorado Anschutz](https://news.cuanschutz.edu/news-stories/your-blog-fda-clears-clinical-trial-using-car-t-cells-to-fight-colorectal-cancer) to begin a clinical trial of genetically engineered CAR T-cells in adults with advanced colorectal cancer and in children with solid tumors who have exhausted standard treatment. Christopher Lieu, MD, of the CU Cancer Center leads the trial, and Michael Verneris, MD, helped develop the therapy. Enrollment is expected to begin around December 2026.

The study is early-stage and first-in-human, meaning its primary job is to learn whether the engineered cells are safe in people and at what dose, not whether they shrink tumors. It enrolls patients who have run out of approved options. That places it at the very front of a long research pipeline rather than at the point where a therapy reaches clinics.

## The Engineered Cells Target Two Signals the Tumor Sends

The cells are designed to recognize B7-H3, a protein found on the tumors, and to use IL-8, a chemical signal the tumors give off, to home in on them. The researchers describe this dual approach as a way to help the cells both find the tumor and stay directed at it.

The design comes from Verneris's earlier laboratory work, published in 2024 in models of pediatric sarcoma. It has not yet been tested in colorectal cancer patients. What the therapy does in a person with advanced colorectal cancer is the open question the trial exists to start answering.

## Solid Tumors Have Blocked CAR-T Where Blood Cancers Did Not

CAR-T therapy drives complete remission in roughly 60 to 90 percent of patients in some approved treatments for leukemia and lymphoma. Against solid tumors it has largely failed. An earlier colorectal CAR-T aimed at a marker called CEA produced no objective responses.

Researchers point to several reasons solid tumors resist these cells. Dense tissue keeps the cells from reaching the tumor. The environment around the tumor suppresses the cells that do arrive. Tumor cells can drop the target the cells are trained to recognize. And the engineered cells often do not survive long enough to finish the work. The B7-H3-and-IL-8 design is one attempt to address that homing and persistence problem, and whether it helps in patients is unknown.

## Cell Therapy Has Reached Its First Milestones Against Solid Tumors

Iovance's lifileucel, a different kind of cell therapy made from a patient's own tumor-fighting T-cells, became the first cell therapy approved for a solid tumor, advanced melanoma, in February 2024. In June 2026, China [approved the first CAR-T for a solid tumor](https://www.aabb.org/news-resources/news/article/2026/07/01/china-approves-world-s-first-car-t-cell-therapy-for-solid-tumors), a gastric cancer, with roughly a 22 percent response rate.

The Colorado clearance is a US trial authorization at the safety-testing stage, not a solid-tumor CAR-T approval. It joins a small group of efforts trying to translate cell therapy from blood cancers into the harder territory of solid tumors.

## Routine Approval Is Still Years Off

Researchers project that routine approval of CAR-T for solid tumors is still years away, with estimates pointing to 2031 to 2035. Median survival in metastatic colorectal cancer runs roughly 11 to 20 months. Most patients being treated today cannot wait for trials like this one to mature. The clearance marks progress in the research, and it does not change the treatment a person can get this year.

## FAQ

**Q: What is CAR T-cell therapy?**
It is a treatment that removes a patient's own immune T-cells, engineers them in a lab to recognize a specific target on cancer cells, and returns them to the body to attack the cancer. Several CAR-T products are already approved for blood cancers such as leukemia and lymphoma.

**Q: Why is CAR-T harder to use against solid tumors than blood cancers?**
Solid tumors are physically dense, so the cells struggle to get in. The tissue around the tumor suppresses the cells that do arrive, tumor cells can shed the target the CAR-T is trained on, and the engineered cells often do not last long. Blood cancers present fewer of these barriers, which is part of why CAR-T has worked better there.

**Q: What is a Phase 1 clinical trial?**
It is the first stage of testing a therapy in people. The main goal is to assess safety and find a workable dose, usually in a small number of patients. It is not designed to prove that the treatment works.

**Q: When will CAR-T be available for colorectal cancer?**
Not soon. This trial is expected to begin enrolling around December 2026 and is testing safety. Researchers estimate routine approval of CAR-T for solid tumors is still years away, with projections in the 2031 to 2035 range.